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Nitric oxide (NO) is essential for vascular
homeostasis and is also a critical modula-
tor of angiogenesis; however, the molecu-
lar mechanisms of NO action during an-
giogenesis remain elusive. We have
investigated the potential relationship be-
tween NO and membrane type 1–matrix
metalloproteinase (MT1-MMP) during en-
dothelial migration and capillary tube for-
mation. Endothelial NO synthase (eNOS)
colocalizes with MT1-MMP at motility-
associated structures in migratory hu-
man endothelial cells (ECs); moreover,
NO is produced at these structures and is
released into the medium during EC mi-
gration. We have therefore addressed
2 questions: (1) the putative regulation of
MT1-MMP by NO in migratory ECs; and
(2) the requirement for MT1-MMP in NO-
induced EC migration and tube forma-
tion. NO upregulates MT1-MMP mem-
brane clustering on migratory human ECs,
and this is accompanied by increased
degradation of type I collagen substrate.
MT1-MMP membrane expression and lo-
calization are impaired in lung ECs from
eNOS-deficient mice, and these cells also
show impaired migration and tube forma-
tion in vitro. Inhibition of MT1-MMP with
a neutralizing antibody impairs NO-
induced tube formation by human ECs,
and NO-induced endothelial migration and
tube formation are impaired in lung ECs
from mice deficient in MT1-MMP. MT1-
MMP thus appears to be a key molecular
effector of NO during the EC migration
and angiogenic processes, and is a poten-
tial therapeutic target for NO-associated
vascular disorders. (Blood. 2007;110:
2916-2923)
© 2007 by The American Society of Hematology
Introduction
Vascular homeostasis is achieved through the fine-tuned regulation
of the integrity of the endothelial cell (EC) monolayer by vasoac-
tive modulators. One of these critical factors is nitric oxide (NO),
which was first identified as the endothelial-derived relaxing factor
responsible for the regulation of vascular tone.1 Indeed, proper
amounts of NO are essential for correct endothelial functioning.
Besides, endothelial dysfunction is characterized by impaired NO
production by ECs, and is critically involved in the initiation and
development of several cardiovascular diseases.2 NO is an essential
mediator of physiologic vascular remodeling in the adult and is also
implicated in cardiovascular pathology.3
Endothelial cell quiescence is disrupted in certain pathophysi-
ologic conditions. A variety of stimuli promote vasodilation and
blood vessel permeability mainly by increasing the production of
NO and vascular endothelial growth factor (VEGF), respectively.
This can subsequently result in initiation of the angiogenic cascade,
giving rise to the production of new capillaries from preexisting
ones.4 Angiogenesis is critical for many physiologic and pathologic
processes such as wound healing and tissue remodeling, and recent
findings suggest that this process may be important in the
development of cardiovascular disorders like atherosclerosis.5
There is also considerable evidence that effective angiogenesis
requires the synthesis of NO by ECs. VEGF upregulates the
expression and activity of endothelial NO synthase (eNOS/
NOS3),6,7 and endothelium-derived NO appears to play an impor-
tant role in each step of angiogenesis, in particular endothelial
migration and tube formation.8-10 Wound healing and angiogenesis
are impaired in eNOS-deficient mice, showing that eNOS activity
is required for proper EC migration, proliferation, and differentia-
tion; moreover, ECs from eNOS-deficient animals show impaired
capillary formation in the Matrigel plug system.11 However, to
date, the molecular effectors of NO action regulating proteolysis
are incompletely defined.
During angiogenesis, ECs undergo a transition from a
quiescent to a polarized migratory phenotype. Migratory ECs
subsequently employ proteolytic enzymes to remodel the base-
ment membrane of the existing capillary. Among these pro-
teases, matrix metalloproteinases (MMPs) are functionally
prominent. MMPs are Zn-dependent endopeptidases that are
capable not only of degrading extracellular matrix (ECM)
components but also of modulating the bioactivity of transmem-
brane receptors and soluble factors.12 In our previous work we
showed that membrane type 1–matrix metalloproteinase (MT1-
MMP), membrane-anchored MMP, plays an important role
during angiogenesis. MT1-MMP expression and activity are
up-regulated during EC migration, and its activity is required for
migration, invasion, and capillary formation in vitro and in
vivo.13-15 MT1-MMP activity appears to be fine-tuned in ECs
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through modulation of its subcellular localization, internaliza-
tion, and dimerization. The subcellular localization of MT1-
MMP depends on its interaction with integrins and on its
trafficking via caveolae; both of these processes are dependent
on the ECM composition.16,17
Since eNOS and MT1-MMP are both important for EC
migration and capillary tube formation and are both regulated by
caveolae,18,19 we have investigated the possibility that NO might
regulate MT1-MMP function during the angiogenic response, and
that MT1-MMP might therefore be a downstream effector of
NO-induced angiogenesis. By using human ECs and lung ECs
from mice deficient in either eNOS or MT1-MMP, we demon-
strate that NO promotes focal clustering and activation of
MT1-MMP at the surface of migrating ECs and that this
protease is essential for proper NO-induced endothelial migra-
tion and capillary tube formation.
Materials and methods
Approval was obtained from the Instituto de Salud Carlos III Institutional
Review Board for these studies.
Antibodies and reagents
The following monoclonal antibodies (mAbs) were as previously de-
scribed13: anti–VE-cadherin TEA1/31, anti-CD31 TP1/15, and anti–MT1-
MMP LEM-2/15 and LEM-2/63. Anti–caveolin-1 mAb (clone 2234) and
anti-eNOS mAb were from BD Transduction Laboratories (Lexington,
KY); anti–ICAM-2 (CD102) and anti-CD16 antibodies were from Pharmin-
gen (San Jose, CA); and anti-phospho eNOS (Ser 1177) antibody was from
Cell Signaling (Danvers, MA). Antitubulin mAb, type IV gelatin, and
bradykinin were from Sigma-Aldrich (St Louis, MO). Type I collagen
(COL I) was from ICN Biomedicals (Costa Mesa, CA). The chemokines
CCL2 ([C-C motif] ligand 2; monocyte chemotactic protein-1) and
CXCL12 ([C-X-C motif] ligand 12; stromal cell–derived factor-1) were
from R&D Systems (Minneapolis, MN). DEA-NONOate and DETA-
NONOate were from Alexis Biochemicals (Carlsbad, CA). SNAP,
L-NAME, DAF-FM–diacetate and DQ-Collagen type I (DQ-COL I) were
from Invitrogen (Carlsbad, CA).
Cells and cell cultures
Human umbilical vein endothelial cells (HUVECs) were obtained and
cultured as previously described.13 ECs were grown on 1% gelatin (GEL).
Mice of the C57BL/6 strain deficient in eNOS or MT1-MMP (Mmp14)
have been previously characterized.11,20 Mouse lung endothelial cells
(MLECs) were purified from wild-type and eNOS or MT1-MMP null mice
as previously described.15 ECs were incubated in serum-free medium for
16 hours before experiments. ECs were stimulated to migrate by disrupting
the monolayer with a scraper (wound-healing) or by seeding at
subconfluence.
Immunofluorescence microscopy
Subconfluent ECs on coverslips coated with GEL were incubated with the
anti–MT1-MMP mAb and labeled with an Alexa 488–conjugated second-
ary mAb. For eNOS staining, cells were permeabilized for 2 minutes with
0.1% Triton X-100, and then incubated with anti-eNOS monoclonal or
rabbit Ab and labeled with an Alexa Cy3–conjugated secondary Ab.
Samples were mounted with Mowiol (Calbiochem, Merck KgaA, Darm-
stadt, Germany) or ProLong Gold (Invitrogen). Samples were examined
under an Axiovert 200 M SP LSM5 fluorescence microscope from Zeiss
(Jena, Germany) equipped with 40/1 NA or 63/1.4 NA oil-immersion
objectives or a confocal microscope Biorad Radiance 2100 (Zeiss) with a
40/1.3 NA or 60/1.4 NA oil-immersion objective. Images were acquired
with an AxiocamHRm digital camera and Axiovision Rel 4.2 software
(Zeiss). Alternatively, a Leica DMI6000 microscope (Leica Microsystems
GmbH, Wetzlar, Germany) equipped with a 40/1.25 NA or 63/1.4 NA
oil immersion objective was used; pictures were acquired with a Leica
DFC350FX digital camera and LAS AF software (Leica). Linear processing
of images was performed with Adobe Photoshop CS software (Adobe, San
Jose, CA). To quantify MT1-MMP clustering on migrating ECs, HUVECs
were treated over a time course with NO donors in 6 independent
experiments; in each experiment, 2 blinded observers examined at least
15 control and treated cells for each time point. For quantitative comparison
of MT1-MMP distribution between wild-type and eNOS-deficient MLECs,
3 blinded observers examined at least 80 cells of either genotype in
3 independent experiments to quantitate cells displaying concentrated
MT1-MMP at lamellipodia/filopodia versus a more diffuse, punctate
pattern.
In situ detection and measurement of NO production
For in situ visualization of NO, we used a specific membrane-permeable
NO probe, DAF-FM–diacetate. MLECs or HUVECs were incubated with
5 M DAF-FM in Hanks balanced salt solution (HBSS) supplemented with
1% fetal bovine serum (FBS) for 30 minutes. ECs were then washed 3 times
with phosphate-buffered saline (PBS) and observed under a Leica TCS
SP2-AOBS confocal microscope equipped with a 40/1.25 NA or 63/1.4
NA objective. For real-time assays, HUVECs were analyzed by time-lapse
confocal microscopy. Fluorescent and phase-contrast images were recorded
at 20-second intervals over 6 minutes. For the NO measurement assays,
HUVECs were pretreated with L-NAME (500 M) and stimulated to
migrate by wound healing. NO production was determined from the
accumulation of nitrites (NO2-) in the cell culture medium after 15 to
30 minutes; nitrites were reduced with acidified NaI and the NO product
detected with a NOA 280 NO analyzer (Sievers Instruments, Boulder, CO).
Peaks were integrated with Origin software (OriginLab, Northampton,
MA).
Flow cytometry analysis
Migrating (subconfluent or wound-healing) HUVECs were incubated with
100 M DEA-NONOate or DETA-NONOate for 3, 6, or 16 hours and
processed as previously described.13 Samples were analyzed in a FACS-
Canto (Becton Dickinson Labware, Lincoln Park, NJ) or Cytomics-FC500
(Beckman-Coulter, Fullerton, CA) flow cytometer.
Western blot assays
ECs were lysed and analyzed as previously described.16
Triton X-114 extraction
Subconfluent HUVECs were treated with 100 M DEA-NONOate or
DETA-NONOate for different times, and cell fractionation was performed
by Triton X-114 extraction. In brief, cells were lysed in 1.5% Triton X-114
at 4°C, and after 5 minutes of centrifugation at 9000g, supernatants were
heated at 37°C for 2 minutes. Hydrophobic (caveolin-1 positive) and
hydrophilic (tubulin positive) phases were collected after 5 minutes of
centrifugation at 9000g. Samples were assayed for Western blot as
described.16
In situ detection of MT1-MMP activity
Since MT1-MMP is a major collagenase in ECs,21 COL I degradation was
used to analyze MT1-MMP activity in these cells. First, we used
a fluorescein-conjugated substrate (DQ-COL I), which emits fluorescence
upon cleavage, to visualize MT1-MMP proteolytic activity at the cell
surface. HUVECs were seeded onto 10 g/mL COL I or DQ-COL I and
were treated with 1 M bradykinin or 100 M DETA-NONOate from 1 to
6 hours. After fixing, samples were visualized under a fluorescence
microscope. An additional assay for measuring COL I degradation was used
in MLECs from different genetic mouse strains. These cells were seeded on
1 mg/mL rat tail COL I (Roche Pharma, Basel, Switzerland) and stimulated
with 1 M bradykinin for 24 hours. After fixing, COL I was immunostained
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with an anti–COL I mAb (Sigma-Aldrich) and samples were visualized
under an Axiovert 200 M SP LSM5 fluorescence microscope (Zeiss). Dark
areas around ECs corresponding to COL I degradation were quantitated
with Laserpix software (Bio-Rad, Hercules, CA). In each experiment,
10 cells were counted.
Cell migration and in vitro angiogenesis assays
Cell migration and in vitro angiogenesis assays were performed as
described previously.13 Briefly, for migration assays 40  103 MLECs were
seeded on GEL-coated Transwell chambers and stimulated to migrate with
bradykinin or NO donors in the upper chamber or toward the chemokines
CCL2 or CXCL12 in the lower chamber. ECs were counted after 16 hours
of migration by fixing and staining with 0.2% violet crystal, 2% ethanol.
For in vitro angiogenesis assays, 10 103 ECs were seeded on Matrigel
(BD Matrigel Basement Membrane Matrix; BD Biosciences, San Jose, CA)
with or without treatments, and cords were counted after 6 hours. ECs were
pretreated for 15 minutes before seeding when anti–MT1-MMP Ab or
control Abs were used. All experiments were run in triplicate.
Statistical analysis
Experimental and control samples were compared for statistical signifi-
cance by using the Student t test.
Results
eNOS and MT1-MMP colocalize at membrane protrusions
of migrating ECs where eNOS is found to be active
Cell migration is a critical step during early angiogenesis and is
tightly regulated by a variety of receptors, ECM components, and
soluble factors, including NO.22-24 MT1-MMP also plays an
essential role in endothelial migration induced by distinct angio-
genic factors in vivo and in vitro.13,14,20 To investigate the potential
relationship between NO and MT1-MMP during angiogenesis, we
first studied the localization and activity of eNOS and MT1-MMP
in human ECs. Our previous work established that MT1-MMP,
together with integrin v3 and caveolin-1, is enriched at lamelli-
podia and filopodia in migratory ECs.13,16,17 We therefore examined
eNOS expression in the cytosolic projections of migrating human
ECs from subconfluent cultures by immunofluorescence. Both
eNOS and MT1-MMP were detected at the lamellipodia and
filopodia of migrating ECs. Confocal microscopy analysis revealed
colocalization of these proteins at these structures (Figure 1A).
Given that EC migration upregulates MT1-MMP activity, we
wondered whether migration might also stimulate eNOS activity at
these sites. We investigated local NO production during endothelial
migration by using the probe DAF-FM, which reacts with NO to
form a fluorescent product; the specificity of this approach was
confirmed by the irresponsiveness of eNOS-deficient ECs (Figure
S1, available on the Blood web site; see the Supplemental Materials
link at the top of the online article). These experiments demon-
strated that NO is produced locally at the lamellipodia and filopodia
of migrating human ECs. This localized production was highly
dynamic with foci of NO production arising and disappearing in a
matter of seconds or minutes throughout the observation period
(Figure 1B and Video S1). We next examined whether this local
NO production was associated with release of NO to the extracellu-
lar medium. ECs induced to migrate in the wound-healing assay
released significantly more NO during the first 15 to 30 minutes
after the induction of migration compared with confluent ECs
(Figure 1C). This increased NO release was blocked by pretreat-
ment of ECs for 1 hour with the NOS inhibitor L-NAME, providing
further evidence for the activation of eNOS during EC migration
(Figure 1C). The colocalization of eNOS and MT1-MMP at
motility-associated structures, together with the activation of eNOS
at these structures and subsequent NO production by migrating
ECs, prompted us to investigate (1) the possible regulation of
MT1-MMP by NO in migrating ECs, and (2) the requirement of
MT1-MMP functional activity during NO-induced EC migration
and tube formation. These 2 questions were addressed by using
both human ECs and murine lung ECs (MLECs) obtained from
mice deficient in eNOS or MT1-MMP.
Figure 1. eNOS is active at motility-associated structures of human endothelial
cells, where it colocalizes with MT1-MMP. (A) Subcellular location of eNOS (red)
and MT1-MMP (green) was analyzed by immunofluorescence double-staining of
subconfluent HUVECs. The merged image reveals colocalization (yellow); arrows
indicate colocalization at membrane protrusions. (B) Migrating HUVECs were
preloaded for 30 minutes with the NO probe DAF-FM, and NO production was clearly
visible at cellular protrusions (top). The lower figure shows representative real-time
capture (n  4) of DAF-FM fluorescence at the lamellipodia of a migrating EC. The
location of NO production was recorded over 6 minutes at lamellipodia in migrating
ECs at 20-second intervals; t  0 indicates the beginning of recording. Note the
appearance and disappearance of NO production at lamellipodia during the recorded
period (bottom, arrowheads). (C) HUVECs were left untreated or treated with
L-NAME for 1 hour. Migration was initiated by disrupting monolayers (“In situ
detection and measurement of NO production”). NO production was measured as the
accumulation of NO2- released into the culture medium over 30 minutes by resting
(confluent) or migrating (wound-healing) HUVECs. The chart shows the arithmetic
mean plus or minus the standard deviation (SD) of the fold induction (FI) over nitrite
release from 3 independent experiments run in duplicate. The absolute value
corresponding to FI  1 was 307 nM. *P  .04.
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Nitric oxide promotes MT1-MMP membrane clustering and COL
I degradation by migrating human ECs
We first investigated the possible effect of NO on MT1-MMP
expression at the surface of migrating ECs. Migratory HUVECs
were treated with the NO donors DEA-NONOate or DETA-
NONOate,25 and MT1-MMP membrane expression was detected
by flow cytometry. NO donors induced a significant up-regulation
of the percentage of cells expressing MT1-MMP at the cell surface,
but this was seen only after 16 hours (Figure 2A); long after the
endogenous NO release observed in migrating cells (Figure 1C).
Western blot of whole-cell lysates indicated that NO-augmented
expression of MT1-MMP is not related to de novo protein synthesis
(Figure 2A). To further explore the regulation of MT1-MMP by NO
we next examined the effect of NO donors on MT1-MMP activity.
No modulation of MT1-MMP activity by NO donors was observed
by fibrinogen or gelatin zymography of whole-cell lysates of
migratory human ECs (data not shown); however, zymography will
not detect possible focal protease activation at sites of MT1-MMP
and eNOS colocalization. Given that MT1-MMP is the main
collagenase in ECs, we therefore seeded migratory subconfluent
ECs onto the fluorescein-conjugated substrate DQ-COL I and
stimulated with DETA-NONOate or the physiologic eNOS activa-
tor bradykinin. Treatment with either agent significantly increased
the percentage of cells displaying DQ-COL I degradation at the cell
membrane (Figure 2B left); DQ-COL I degradation was more
evident at membrane lamellipodia and filopodia (Figure 2B right;
Figure S2). This increased MT1-MMP activity was detected after
treatment for 3 and 6 hours; after 16 hours, DQ-COL I degradation
returned to the level detected in unstimulated cells (data not
shown). Only nonspecific signals were detected in subconfluent
ECs grown on nonfluorescent COL I or in confluent ECs on
DQ-COL I (Figure 2B right, and data not shown).
The identification of focal activation of MT1-MMP by NO
donors at times when its surface expression appeared to be
unaltered suggests that NO might regulate the distribution of
MT1-MMP within the membrane. Immunofluorescence showed
that MT1-MMP clustering was modulated by exposure to NO
donors: DEA-NONOate and DETA-NONOate both increased the
proportion of MT1-MMP located in discrete membrane-domain
clusters on migrating ECs, with significantly increased clustering
detected after 1, 3, and 6 hours of exposure to DEA-NONOate and
after 3 and 6 hours of exposure to DETA-NONOate (Figure 2C).
The different timing of these responses reflects the rapid and slow
release of NO from DEA-NONOate and DETA-NONOate, respec-
tively. After exposure to DETA-NONOate for 16 hours, clustering
returned to the level of nontreated cells. To further define the
mechanism of NO-mediated MT1-MMP membrane compartmenta-
tion, we examined the distribution of MT1-MMP by cell fraction-
ation. The ratio of caveolar membrane MT1-MMP to cytosolic
MT1-MMP was not altered by exposure to NO donors for 1, 3, 6, or
16 hours (Figure 2D and data not shown). These data thus indicate
that short- to medium-term exposure to NO induces MT1-MMP
clustering and activity at motility-associated structures and suggest
that NO might directly or indirectly regulate MT1-MMP activity at
specific sites on the cell surface during EC migration.
Nitric oxide is necessary for proper MT1-MMP membrane
expression, localization, activity, and function in migratory ECs
To examine the role of endogenously produced NO in the
regulation of MT1-MMP homeostasis, we analyzed the expression
and localization of MT1-MMP in MLECs from wild-type and
eNOS-deficient mice. Surface expression of MT1-MMP, but not
CD31, was decreased in MLECs from eNOS-deficient mice by an
average rate of 50% (Figure 3A, top). However, there were no
apparent differences in total MT1-MMP expression (Figure 3A
bottom), consistent with the effect of NO on human ECs (Figure
2A). Immunofluorescence analysis showed that MT1-MMP was
present at membrane protrusions of migrating MLECs regardless
Figure 2. NO regulates MT1-MMP activity and membrane clustering in migrating ECs. (A) Migrating HUVECs were treated with 100 M DEA-NONOate (DEA) or
DETA-NONOate (DETA) for 3, 6, or 16 hours, and membrane expression of MT1-MMP was detected by flow cytometry. The chart shows the mean plus or minus SD of the fold
induction of the percent of MT1-MMP–positive cells from 3 independent experiments (left). None indicates nonstimulated controls. Total cellular expression of MT1-MMP was
analyzed by Western blot in migratory HUVECs treated for 16 hours with 100 M DETA-NONOate (DETA) or 20 ng/mL PMA (right). VE-cadherin is shown as loading control.
The fold induction relative to nonstimulated (NS) cells was estimated from densitometric analysis of 5 independent experiments. (B) NO increases collagenolytic activity at the
cell membrane of migratory ECs. HUVECs were seeded at subconfluence onto 10 g/mL COL I or DQ-COL I and left untreated (None) or treated with 100 M DETA-NONOate
or 1 M bradykinin for 3 or 6 hours. DQ-COL I cleavage was visualized by its fluorescent product. Data are the means plus or minus SD of the percent of cells showing DQ-COL
I fluorescence (an average of 40 cells were counted per condition); *P  .05; **P  .02 (left). DQ-COL I cleavage at cell protrusions was increased in bradykinin-treated ECs
(right; arrowheads). (C) NO increases membrane clustering of MT1-MMP. The subcellular location of MT1-MMP was detected by immunostaining of subconfluent HUVECs
treated with 100 M DEA-NONOate (DEA) and DETA-NONOate (DETA) for different periods (left). Two blinded observers independently quantitated the number of clusters per
cell. Data show the means plus or minus SD of at least 80 cells per condition from 6 independent experiments. *P  .04; **P  .02 (right). (D) The distribution of MT1-MMP
between caveolar membrane and cytosolic fractions was assayed by cell membrane isolation with Triton X-114 from HUVECs treated with DEA-NONOate or DETA-NONOate
as in panel C. One representative experiment of 4 performed is shown. The fold induction relative to nonstimulated (NS) cells was estimated from densitometric analysis.
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of the expression of eNOS; however, the pattern of MT1-MMP
staining at these protrusions differed between wild-type and
eNOS-deficient MLECs (Figure 3B top, and Figure S3): compared
with wild-type cells, the percentage of eNOS-null MLECs showing
concentrated MT1-MMP staining at lamellipodia or filopodia was
decreased and the percentage showing pointlike MT1-MMP stain-
ing was increased (Figure 3B bottom). In addition, image analysis
showed that MT1-MMP–positive clusters spanned a wider area at
the cell membrane in wild-type MLECs compared with eNOS-
deficient cells (Figure S3). These data are consistent with the
modulation of MT1-MMP clustering by NO donors observed in
HUVECs (Figure 2C).
Collagenolytic activity in subconfluent eNOS-deficient MLECs
was significantly reduced compared with wild-type cells; more-
over, the collagenolytic activity of eNOS-deficient MLECs was
similar to the level of activity in MLECs from MT1-MMP–
deficient mice (Figure 3C). In addition, bradykinin increased COL I
degradation by wild-type but not by eNOS-deficient cells (Figure
3C). These results indicate that MT1-MMP activity is decreased in
the absence of endogenous NO production via eNOS, consistent
with the regulation of MT1-MMP activity by NO observed in
HUVECs (Figure 2B).
MT1-MMP activity is known to be important for endothelial
migration and the formation of capillary tubes.13,14 To dissect the
influence of endogenous NO on MT1-MMP function we therefore
compared the effect of inhibiting MT1-MMP on the ability of
wild-type and eNOS-deficient MLECs to migrate and form capil-
lary cords. Consistent with our own and others’ earlier reports,11,26
eNOS-deficient MLECs migrated and formed cords less efficiently
than their wild-type counterparts (Figure 3D). These defects
seemed to be directly related to the absence of NO production
because NO donors increase cell migration and tube formation in
eNOS-deficient MLECs (data not shown). In wild-type MLECs,
exposure to the inhibitory anti–MT1-MMP mAb LEM-2/6313
inhibited migration by 50%; in contrast, this mAb had no effect on
constitutive migration by eNOS-deficient MLECs (Figure 3D top).
Similarly, mAb LEM-2/63 inhibited cord formation by 30% in
wild-type MLECs but had no effect on eNOS-deficient cells
(Figure 3D bottom). In addition, CCL2 (an MT1-MMP–dependent
stimulus) did not induce migration or cord formation in eNOS-
deficient MLECs, whereas the action of CXCL12 (an MT1-MMP–
independent stimulus) was unaffected.14 These data suggest that
proper function of MT1-MMP during endothelial migration and
tube formation requires the presence of eNOS and the associated
production of NO by ECs.
NO-induced endothelial migration and capillary tube formation
require MT1-MMP expression and activity
Having established that NO regulates MT1-MMP in migratory
ECs, we addressed whether this protease is in fact required for NO
induction of EC migration and/or tube formation. Bradykinin-
induced tube formation by human ECs was specifically diminished
by the inhibitory anti–MT1-MMP mAb LEM-2/15,13 indicating
Figure 3. NO is required for proper MT1-MMP homeostasis and function in migratory ECs. (A) Subconfluent MLECs from wild-type and eNOS-null mice were analyzed
for MT1-MMP membrane expression by flow cytometry. The means plus or minus SD of the percent of MT1-MMP–positive cells from 5 independent experiments are
represented. *P  .01 (versus eNOS/) (top). The Western blot shows MT1-MMP expression in total cell lysates from wild-type and eNOS-deficient MLECs (bottom).
MT1-MMP expression in HUVECs is shown for comparison. (B) MT1-MMP subcellular localization was visualized by immunofluorescence staining in MLECs from wild-type
and eNOS-deficient mice; arrowheads indicate MT1-MMP staining at membrane protrusions (top). The chart shows quantification of the percentage of cells showing MT1-MMP
clusters at lamellipodia/filopodia versus pointlike staining (n  80 cells counted from 3 independent experiments) (bottom). (C) MT1-MMP activity was detected as the area of
COL I degradation (dark) by wild-type and eNOS-deficient and MT1-MMP–deficient MLECs (top). Arrowheads indicate individual endothelial cells. One representative
experiment is shown. The chart shows quantification of COL I degradation areas from wt (/) and MT1-MMP– and eNOS-deficient cultures (-/-). The effect of stimulation with
the eNOS activator bradykinin on COL I degradation is shown. Data are the means plus or minus SD (n  5 for MT1-MMP and n  4 for eNOS; bottom). Absolute value
corresponding to FI  1 is 94.5 m2. #P  .01 (versus /); *P  .01 (versus NS). (D) Top panel: Migration of wild-type and eNOS-null MLECs was analyzed in Transwell
chambers after exposure of cells for 16 hours to the neutralizing anti–MT1-MMP mAb LEM-2/63 or control anti-CD31 mAb. Treatments with CCL2 and CXCL12 (10 nM) were
included as controls of MT1-MMP–dependent and MT1-MMP–independent migration, respectively. Data are the means plus or minus SD of the FI above untreated wild-type
cells from 3 independent experiments. The absolute value corresponding to FI  1 was 18 migrated cells/field. *P  .05; **P  .02 (versus None); P  .02 (versus No Ab);
#P  .01 (versus eNOS/). Bottom panel: Cord formation by wild-type and eNOS-null MLECs was analyzed by seeding onto Matrigel in the presence of the anti–MT1-MMP
or control anti-CD31 mAbs. Treatments with CCL2 and CXCL12 (10 nM) were included as controls of MT1-MMP dependence and independence, respectively. Cord formation
was quantified after 6 hours. Data are the means plus or minus SD of the FI above tube formation by untreated wild-type cells from 5 (eNOS/) and 4 (eNOS-/-) independent
experiments. The absolute value corresponding to FI  1 was 48.21 cords/field. *P  .04 (versus None); P  .01 (versus No Ab). eNOS-/- MLECs were significantly less
efficient at forming cords than eNOS/MLECs; #P  .04 (versus eNOS/None). All experiments were run in triplicate.
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that MT1-MMP is required for NO-induced capillary tube forma-
tion by human ECs (Figure 4A). To confirm this, we examined
migration and capillary tube formation in ECs from MT1-MMP–
deficient mice. No major differences were observed in the amounts
of eNOS or phospho-eNOS between wild-type and MT1-MMP–
deficient MLECs (Figure 4B top). Moreover, comparison of eNOS
subcellular localization showed a similar pattern of staining in both
cell types, and NO production detected by DAF-FM staining was
also comparable (Figure 4B bottom, and Figure S4). These data
thus indicate that eNOS expression, localization, and activity are
similar in wild-type and MT1-MMP–deficient MLECs. To test the
effect of endogenous NO, we treated MLECs with the eNOS
activator bradykinin. Consistent with our earlier work,14,15 ECs
deficient in MT1-MMP migrated and formed cords less efficiently
than their wild-type counterparts (Figure 4C,D). Bradykinin signifi-
cantly increased migration and capillary tube formation by wild-
type MLECs, but had no effect on MT1-MMP–deficient MLECs
(Figure 4C,D). Similar effects were observed with the MT1-MMP–
dependent stimulus CCL2 (Figure 4C,D), whereas migration and
tube formation induced by the MT1-MMP–independent inducer
CXCL12 was not affected. The integrity of other bradykinin-
activated signaling pathways in MT1-MMP–null cells was demon-
strated by the phosphorylation of ERK upon bradykinin stimulation
(Figure S5).
Discussion
In this report we identify a functional link between the bioactive
molecule NO and the protease MT1-MMP during endothelial cell
migration and cord formation. We show that eNOS and MT1-MMP
colocalize and are both activated at motility-associated membrane
protrusions. Analysis of the molecular mechanisms involved in this
interplay reveals that NO increases MT1-MMP membrane cluster-
ing and activity in migrating ECs. The presence of eNOS, the
enzyme responsible for NO production in ECs, is required for
proper MT1-MMP expression and distribution at the cell surface,
collagenolytic activity, and function in migratory ECs. Finally,
MT1-MMP is required for NO-induced endothelial migration and
formation of capillary tubes in vitro.
The transition of quiescent endothelial cells to a migratory state
can be triggered by a variety of stimuli. Both eNOS and MT1-
MMP are implicated in endothelial activation and both are there-
fore potential targets of signaling pathways that initiate endothelial
migration and the angiogenic response. Our identification of eNOS
at the lamellipodia and filopodia of migratory human ECs is similar
to recently published findings27 and suggests a possible interplay
between eNOS and MT1-MMP.13 Indeed, confocal analysis demon-
strated a degree of colocalization of eNOS and MT1-MMP at these
structures. We have previously identified a molecular complex
composed of MT1-MMP, caveolin-1, and v3 integrin present at
migration-associated protrusions of ECs17; our present results thus
suggest eNOS as a possible additional molecular partner that might
regulate this complex during the migratory response. Moreover, we
have also found that eNOS compartmentation in ECs can be
regulated by growth on different ECM substrates (data not shown)
in a similar way to MT1-MMP.14 It thus appears that the compart-
mentation of eNOS and MT1-MMP can be modulated by related
molecular pathways. The identity of these pathways remains
obscure but might involve caveolae-mediated internalization and/or
regulated palmitoylation.17,28-30
The detection of NO production at EC membrane protrusions
and the release of NO by migratory ECs provide the first
demonstration of the activation of eNOS during EC migration. This
activation may act as a positive feedback mechanism in angiogen-
esis and other pathophysiologic contexts. An especially notable
feature of the NO production detected at membrane protrusions
was that it was highly dynamic, with concentrated bursts detected
by DAF-FM fluorescence arising and disappearing over a period of
seconds to minutes. Several signaling pathways could potentially
underlie this dynamic up-regulation of eNOS activity at defined
sites of the cell membrane of migrating ECs. For example, calcium
Figure 4. NO-induced migration and cord formation requires MT1-
MMP expression and activity. (A) HUVECs were treated with 1 M
bradykinin in the presence or absence of anti–MT1-MMP (mAb LEM-2/15)
or control anti-CD31 and were seeded onto Matrigel. Cord formation was
quantified after 6 hours. Data are the means plus or minus SD of the
FI above tube formation by untreated cells from 3 experiments. The
absolute value corresponding to FI  1 was 59.5 cords/field. *P  .01
(versus NS); #P  .01 (versus No Ab). All experiments were run in
triplicate. (B) Top panel: Western blot of eNOS expression (phosphorylated
and total) in MLECs from wild-type (/) and MT1-MMP null mice (/).
Bottom panel: eNOS localization was visualized by immunofluorescence
and NO production by DAF-FM labeling in wild-type and MT1-MMP–null
MLECs. (C) MLECs from wild-type and MT1-MMP–null mice were induced
to migrate on Transwell chambers during 16 hours by addition of 1 M
bradykinin in the upper chamber, or toward 10 nM CCL2 or CXCL12 in the
lower chamber. Data are the means plus or minus SD of the fold induction
(FI) from 4 independent experiments. The absolute value corresponding to
FI  1 was 15.25 migrated cells/field. *P  .03; **P  .02 (versus None);
#P  .02 (versus MT1-MMP/None). (D) Wild-type and MT1-MMP–null
MLECs were treated as indicated with bradykinin (1 M) or with CCL2 or
CXCL12 (10 nM) and seeded onto Matrigel. Cord formation was quantified
after 6 hours. Data are the means plus or minus SD of the FI above tube
formation by untreated cells (None), of several independent determina-
tions (n  5 for None and bradykinin, n  4 for CCL2, and n  3 for
CXCL12). The absolute value corresponding to FI  1 was 50.7 cords/
field. *P  .03; **P  .01; (versus None); # P  .01 (versus MT1-
MMP/ None).
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waves are induced at the leading edge of migratory ECs.31 Another
possible mechanism involves the small GTPase Rac, which plays
roles in EC migration and the formation of membrane protrusions32
and acts as an upstream regulator of eNOS in VEGF-induced
increases in EC permeability.33 The activity of eNOS can also be
up-regulated by phosphorylation at Ser 1177 by Akt, and the Akt
pathway is required for endothelial migration and angiogenesis.34,35
In our previous work we characterized the activation and action
of MT1-MMP in EC migration.13 Here, we report that MT1-MMP
is a direct or indirect downstream effector of NO in migratory ECs,
via a mechanism involving focal clustering of MT1-MMP. MT1-
MMP clustering at the cell surface of human ECs appears to be
directly related to the amount of NO available, since the timing of
clustering induced by DEA-NONOate and DETA-NONOate corre-
late with the rapid and delayed release of NO by these agents. In
addition, NO donors or bradykinin increased MT1-MMP collageno-
lytic activity at EC membrane protrusions at times similar to those
at which clustering is induced, suggesting that the 2 events are
related. In contrast to the regulation of MT1-MMP expression by
migration,13 NO does not affect the total amount of MT1-MMP
protein detected by Western blot; similarly, the flow cytometry and
cell fractionation do not show general or sustained effects on
MT1-MMP levels at the membrane in the initial period after
exposure to NO, when MT1-MMP clustering and increased activity
are detected. Considering the dynamic nature of NO production at
membrane protrusions (Figure 1B), it may be that the MT1-MMP
clustering is similarly dynamic and fluctuating. Nonetheless, the
increased proportion of cells expressing MT1-MMP after 16 hours
of exposure to NO donors might indicate a more general regulation
of MT1-MMP in the longer term response of ECs to NO activators,
consistent with the reduced membrane expression of MT1-MMP
observed in eNOS-deficient MLECs. But over the short term it is
important to consider that MT1-MMP clustering and colocalization
with eNOS is highly focused, and only affects a subset of the total
cellular MT1-MMP content. It is therefore possible that MT1-
MMP clustering and eNOS colocalization involve localized cy-
cling between the cytosol and cell membrane that is not detectable
by whole-cell assays such as flow cytometry and crude cell
fractionation. Nitric oxide has recently been proposed to play an
important role in protein trafficking,36 and our data will reinforce
the view of NO as a critical regulator of protein compartmentation
at local sites within cells. Whether NO regulates MT1-MMP
mobilization to the membrane, its internalization, or both, and
through which kind of vesicles and/or microdomains, will require
further investigation.
A role for MT1-MMP as an effector of NO during EC
migration is strongly supported by the experiments in eNOS-
deficient MLECs, which demonstrate that endogenous NO is
required for MT1-MMP homeostasis in ECs: (1) MT1-MMP
localization at membrane protrusions is altered in the absence of
eNOS, strongly supporting a role for NO in regulating MT1-
MMP compartmentation; (2) COL I degradation is reduced in
the absence of NO; and (3) MT1-MMP function in endothelial
migration and tube formation is impaired in ECs deficient in
eNOS and therefore NO production. It is noteworthy that
MT1-MMP regulation by NO in ECs seems to take place in
migratory conditions associated to distinct pathophysiologic
processes but not in the quiescent endothelial monolayer. Since
MT1-MMP is not universally required for all angiogenic
responses,14,37 we also addressed whether MT1-MMP might be
an active downstream effector during NO-induced angiogenic
responses. Experiments in MLECs from MT1-MMP–deficient
mice and in human ECs treated with a neutralizing anti–MT1-
MMP mAb confirmed that MT1-MMP is required for proper
NO-induced endothelial migration and capillary tube formation
in standard in vitro assays. The role played by MT1-MMP
during NO-induced EC migration and angiogenesis might
involve direct action on the ECM or an indirect action involving
the modulation of the bioactivity of distinct substrates.
In summary, we have identified a functional interplay
between NO and MT1-MMP during endothelial migration. NO
regulates proper MT1-MMP expression, compartmentation,
activity, and function in ECs, and MT1-MMP is required for
efficient NO-induced capillary tube formation. This cooperation
between NO and MT1-MMP might act as an amplification loop
during angiogenesis. NO represents one of the most important
defenses against cardiovascular disease; endothelial dysfunc-
tion, which involves altered production of NO, is involved in the
development of important pathologies such as atherosclero-
sis.2,38 The recent identification of MT1-MMP as a factor
involved in neointima formation39 further highlights the poten-
tial of this protease as a therapeutic target for the treatment of
atherosclerotic disease.
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